Clinical Case 1/2 –

No easy transitions in maintaining recovery
Two years after starting the suboxone treatment, Mary had a craving for heroin. She stopped taking suboxone for three days, then got heroin. She used it for two months, then one night decided to go back on suboxone before being in withdrawal from the …
Read more on Times Herald-Record

Titan Pharmaceuticals Announces Confirmation of Meeting With FDA Regarding …
Probuphine is an investigational subdermal implant designed to deliver continuous, around the clock blood levels of buprenorphine for six months following a single treatment, and to simplify patient compliance and retention. Buprenorphine, an approved …
Read more on Marketwired (press release)

Purdue Pharma L.P. Receives FDA Approval For 15 mcg/hour Dosage Strength …
24, 2013 /PRNewswire/ — Purdue Pharma L.P. announced that the U.S. Food and Drug Administration (FDA) approved a new 15 mcg/hour dosage strength of Butrans® (buprenorphine) Transdermal System CIII, which will provide an additional titration option …
Read more on PR Newswire (press release)

More Buprenorphine Treatment Information…

Comments are closed.